Tracer library / [211At]At-211-APBA-FAPI

[211At]At-211-APBA-FAPI

Also written as At-211-APBA-FAPI

Radionuclide: At-211 t½ 431 min
Modality: Therapy
Production route: —
Stage: Preclinical
Syntheses indexed: 1

Glioma and brain tumours FAP-directed radioligand therapy

What it is

Compound class: FAP inhibitor (FAPI)-based small molecule with albumin binder
Target / mechanism: Fibroblast activation protein-α (FAPα) PMID 39342682
Clinical application: Glioma PMID 39342682
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
—	—	—	>60%	—	APBA-FAPI	39342682 2024 Eur J Med Chem

Need this precursor?We can point you to suppliers for [211At]At-211-APBA-FAPI, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 39342682: 'APBA-FAPI'. Stage set/updated at stage 39 from PMID 39342682: '211At-APBA-FAPI exhibits good targeting in murine xenograft models, showing obviously longer tumor retention than previously-reported radioastatinated compound.'.